Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia

American Journal of Medicine

Volumn 131, Issue 3, 2018, Pages 317.e11-317.e22

  Yu, Oriana ^a,b   Azoulay, Laurent ^a,c,d   Yin, Hui ^a   Filion, Kristian B ^a,c   Suissa, Samy ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Diabetes; Hypoglycemia; Sulfonylurea

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DRUG EXPOSURE; FALLING; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEIZURE; CHEMICALLY INDUCED; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 85035122005     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2017.09.044     Document Type: Article

References (24)

1. Harper, W., Clement, M., Goldenberg, R., et al. Policies, guidelines and consensus statements: pharmacologic management of type 2 diabetes-2015 interim update. Can J Diabetes 39 (2015), 250–252.
2. Bailey, T., Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med 126 (2013), S10–S20.
3. Holden, S.E., Currie, C.J., Mortality risk with sulphonylureas compared to metformin. Diabetes Obes Metab 16 (2014), 885–890.
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 854–865.
5. Morgan, C.L., Mukherjee, J., Jenkins-Jones, S., Holden, S.E., Currie, C.J., Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Diabetes Obes Metab 16 (2014), 957–962.
6. van Dalem, J., Brouwers, M.C., Stehouwer, C.D., et al. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ, 354, 2016, i3625.
7. Schloot, N.C., Haupt, A., Schutt, M., et al. Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: how big is the problem? Which patients are at risk?. Diabetes Metab Res Rev 32 (2016), 316–324.
8. Zoungas, S., Patel, A., Chalmers, J., et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363 (2010), 1410–1418.
9. Garcia Rodriguez, L.A., Perez Gutthann, S., Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 45 (1998), 419–425.
10. Herrett, E., Gallagher, A.M., Bhaskaran, K., et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 44 (2015), 827–836.
11. Jick, S.S., Kaye, J.A., Vasilakis-Scaramozza, C., et al. Validity of the general practice research database. Pharmacotherapy 23 (2003), 686–689.
12. Burns, E.M., Rigby, E., Mamidanna, R., et al. Systematic review of discharge coding accuracy. J Public Health (Oxf) 34 (2012), 138–148.
13. Schneeweiss, S., Rassen, J.A., Glynn, R.J., Avorn, J., Mogun, H., Brookhart, M.A., High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20 (2009), 512–522.
14. Wright, A.D., Cull, C.A., Macleod, K.M., Holman, R.R., Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications 20 (2006), 395–401.
15. Pietraszek, A., Gregersen, S., Hermansen, K., Alcohol and type 2 diabetes. A review. Nutrition, metabolism, and cardiovascular diseases : NMCD. 20 (2010), 366–375.
16. Frier, B.M., Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol 10 (2014), 711–722.
17. Del Prato, S., LaSalle, J., Matthaei, S., Bailey, C.J., Tailoring treatment to the individual in type 2 diabetes practical guidance from the global partnership for effective diabetes management. Int J Clin Pract 64 (2010), 295–304.
18. Whitmer, R.A., Karter, A.J., Yaffe, K., Quesenberry, C.P. Jr, Selby, J.V., Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301 (2009), 1565–1572.
19. Johnston, S.S., Conner, C., Aagren, M., Ruiz, K., Bouchard, J., Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes Metab 14 (2012), 634–643.
20. Leiter, L., Yale, J.-F., Chiasson, J.-L., Harris, S., Kleinstiver, P., Sauriol, L., Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 29 (2005), 186–192.
21. Mellbin, L.G., Ryden, L., Riddle, M.C., et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 34 (2013), 3137–3144.
22. Hanefeld, M., Frier, B.M., Pistrosch, F., Hypoglycemia and cardiovascular risk: is there a major link?. Diabetes Care 39:suppl 2 (2016), S205–S209.
23. Fu, H., Xie, W., Curtis, B., Schuster, D., Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis. Curr Med Res Opin 30 (2014), 1787–1793.
24. Davis, S.N., Shavers, C., Costa, F., Differential gender responses to hypoglycemia are due to alterations in CNS drive and not glycemic thresholds. Am J Physiol Endocrinol Metab 279 (2000), E1054–E1063.